Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Abstract Background Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1). Canakinumab is a human monoclonal antibody against Interleukin-1 beta (IL-1β), licensed for the t...

Full description

Bibliographic Details
Main Authors: Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins, Paul Brogan
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Canakinumab
Cryopyrin-associated periodic syndrome (CAPS)
Vial-sharing
Child
Paediatric
Online Access:http://link.springer.com/article/10.1186/s12969-019-0335-4

Internet

http://link.springer.com/article/10.1186/s12969-019-0335-4

Similar Items